The Artificial Pancreas has the potential to become a huge leap forward in diabetes care. As anxious as all of us are to push the boundaries in diabetes technology, we can’t forget the importance of clinical trials; nothing will move forward without real patients ready and willing to strap on the gear and let researchers observe them for hours on end, most of the time in a clinical setting.
That might not seem like the…
Read more »
More islet cell research to share with you today:
We’ve been covering quite a few companies working hard at finding ways to protect islets from immune system attack. First we profiled Cerco Medical, which is also the subject of a documentary film, and a couple of weeks ago we checked in with ViaCyte, of San Diego. Both of those companies are working with stem cells, but today’s company, Canada’s Sernova, is kicking it old school…
Read more »
By
AmyT on
January 5, 2012
Childbirth and diabetes were once considered mutually exclusive. Thankfully, those days are over. But aiming for a healthy baby — and an uncomplicated birth — when you’re living with diabetes is still a very tall order. It can be scary. And no one really wants to have a C-section, right? (I sure didn’t, x3). Today, D-author and fellow mother of three Amy Stockwell Mercer joins us once more for a special report on new research…
Read more »
Finding a less invasive method of taking insulin seems to be all the rage these days. Although the once-hailed Exhubera fizzled away, researchers have not given up on the “holy grail” of oral insulin. Aside from Mannkind’s Afrezza, which is delayed and controversial, there’s another kind of oral insulin that might be making its mark in the diabetes marketplace… eventually.
Meet MonoSol Rx.
This New Jersey-based company has created PharmFilm, a thin, postage-sized film that…
Read more »
Last week, the New York Chapter of the Juvenile Diabetes Research Foundation hosted their annual research briefing. Many chapters around the country host similar research briefings, and I was excited to find out that our local meeting would feature Dr. Sanjoy Dutta, Director of Glucose Control Therapies within the Treatment Therapies Program.
I want to note that although there’s been a lot of controversy surrounding the addition of treatment goals to JDRF’s mission, I whole-heatedly…
Read more »
